Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Dalton Transactions

• Publication date

  2018-09-11

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1039/c8dt02236dPMID 30112527
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Half-Sandwich Ru(II) and Os(II) Bathophenanthroline Complexes Containing a Releasable Dichloroacetato Ligand

  2018cited by this paper
• Oncosis-inducing cyclometalated iridium(iii) complexes

  2018cited by this paper
• Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development.

  2018cited by this paper
• Aquaporins in cancer development: opportunities for bioinorganic chemistry to contribute novel chemical probes and therapeutic agents.

  2018cited by this paper
• A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer.

  2017cited by this paper
• Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells

  2017cited by this paper
• Novel Antitumor Platinum(II) Conjugates Containing the Nonsteroidal Anti-inflammatory Agent Diclofenac: Synthesis and Dual Mechanisms of Antiproliferative Effects.

  2017cited by this paper
• Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin.

  2016cited by this paper
• Kisspeptin 10 inhibits the Warburg effect in breast cancer through the Smad signaling pathway: both in vitro and in vivo.

  2016cited by this paper
• Cytoplasmic vacuolization in cell death and survival

  2016cited by this paper
• Triple-negative breast cancer: treatment challenges and solutions

  2016cited by this paper
• BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds.

  2016cited by this paper
• Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.

  2015cited by this paper
• Key roles of aquaporins in tumor biology.

  2015cited by this paper
• Current approaches in treatment of triple-negative breast cancer

  2015cited by this paper
• Effect of melatonin on oncosis of myocardial cells in the myocardial ischemia/reperfusion injury rat and the role of the mitochondrial permeability transition pore.

  2015cited by this paper
• Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis

  2015cited by this paper
• A dual-targeting, apoptosis-inducing organometallic half-sandwich iridium anticancer complex.

  2014cited by this paper
• Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine

  2014cited by this paper
• Development of anticancer agents: wizardry with osmium.

  2014cited by this paper
• Mito-DCA: A Mitochondria Targeted Molecular Scaffold for Efficacious Delivery of Metabolic Modulator Dichloroacetate

  2014cited by this paper
• Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy

  2014cited by this paper
• A Breast Cancer Stem Cell-Selective, Mammospheres-Potent Osmium(VI) Nitrido Complex

  2014cited by this paper
• Cytotoxic Triosmium Carbonyl Clusters: A Structure–Activity Relationship Study

  2014cited by this paper
• Aquaporins.

  2013cited by this paper
• A model for cardiomyocyte cell death: insights into mechanisms of oncosis.

  2013cited by this paper
• Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib

  2013cited by this paper
• Mirror-Image Organometallic Osmium Arene Iminopyridine Halido Complexes Exhibit Similar Potent Anticancer Activity

  2013cited by this paper
• Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.

  2012cited by this paper
• Aquaporin-5: A Marker Protein for Proliferation and Migration of Human Breast Cancer Cells

  2011cited by this paper
• Differences in the cellular response and signaling pathways between cisplatin and monodentate organometallic Ru(II) antitumor complexes containing a terphenyl ligand.

  2011cited by this paper
• Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells.

  2011cited by this paper
• Organometallic osmium arene complexes with potent cancer cell cytotoxicity.

  2010cited by this paper
• Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients.

  2010cited by this paper
• Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix‐metalloproteinase expression

  2010cited by this paper
• Metabolic Modulation of Glioblastoma with Dichloroacetate

  2010cited by this paper
• In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model.

  2010cited by this paper
• Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC

  2010cited by this paper
• Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.

  2010cited by this paper
• Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism.

  2009cited by this paper
• Cell Adhesion Molecules: Role and Clinical Significance in Cancer

  2009cited by this paper
• Osmium carbonyl clusters containing labile ligands hyperstabilize microtubules.

  2009cited by this paper
• Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.

  2009cited by this paper
• Induction of apoptosis by hexaosmium carbonyl clusters

  2009cited by this paper
• Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer

  2008cited by this paper
• Neutral red uptake assay for the estimation of cell viability/cytotoxicity

  2008cited by this paper
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• Cytotoxicity, mutagenicity, cellular uptake, DNA and glutathione interactions of lipophilic trans-platinum complexes tethered to 1-adamantylamine.

  2008cited by this paper
• Regulation of the actin cytoskeleton in cancer cell migration and invasion.

  2007cited by this paper
• Metabolic Targeting as an Anticancer Strategy: Dawn of a New Era?

  2007cited by this paper
• A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

  2007cited by this paper
• Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells

  2005cited by this paper
• Cell shrinkage as a signal to apoptosis in NIH 3T3 fibroblasts

  2005cited by this paper
• Cellular processing of platinum anticancer drugs

  2005cited by this paper
• Why do cancers have high aerobic glycolysis?

  2004cited by this paper
• Ruthenium antimetastatic agents.

  2004cited by this paper
• An investigation of the genotoxic effects of N-nitrosomorpholine in mammalian cells.

  2004cited by this paper
• Evaluation of the genotoxic potential of some microbial volatile organic compounds (MVOC) with the comet assay, the micronucleus assay and the HPRT gene mutation assay.

  2002cited by this paper
• Molecular cloning of Porimin, a novel cell surface receptor mediating oncotic cell death

  2001cited by this paper
• A cell surface receptor defined by a mAb mediates a unique type of cell death similar to oncosis.

  1998cited by this paper

• Organometallic Half-Sandwich Complexes of 1,10-Phenanthroline Derivatives with Improved Solubility, Albumin-Binding, and Nanoformulation Potential Targeting Drug Resistance in Cancer

  2025cites this paper
• Highly effective Ru(II) and Os(II) half-sandwich complexes induce cytotoxicity in cancer cells through combined mitochondrial and endoplasmic reticulum stress.

  2025cites this paper
• Influence of the bridging 4′-pyridyl-2,2′:6′,2″-terpyridine chelate ligands on the rate of aqua substitution from the terminal Pt(II) centres of heterometallic Ru Pt complexes

  2025cites this paper
• State of the art in organometallic ruthenium metallodrugs for breast cancer treatment: Advances and innovations

  2025cites this paper
• Enhanced Cytotoxicity of Half-Sandwich Ruthenium(II) Complex Containing Nitro-Substituted Salicyllimidazo[1,5-a]pyridine toward Hormone-Independent Triple-Negative Breast Cancer Cells.

  2025cites this paper
• Multifunctional nanocomposites utilizing ruthenium (II) complex/manganese (IV) dioxide nanoparticle for synergistic reinforcing radioimmunotherapy

  2024cites this paper
• Recent trends in the design and delivery strategies of ruthenium complexes for breast cancer therapy.

  2024cites this paper
• A Cyclometalated Ruthenium(II) Complex Induces Oncosis for Synergistic Activation of Innate and Adaptive Immunity.

  2024cites this paper
• Effects induced by η6-p-cymene ruthenium(II) complexes on Langmuir monolayers mimicking cancer and healthy cell membranes do not correlate with their toxicity.

  2024cites this paper
• Lysosome-targeted ruthenium(II) complex encapsulated with pluronic® F-127 induces oncosis in A549 cells

  2024cites this paper
• A comprehensive review on metallodrugs in breast cancer treatment

  2023cites this paper
• Neuroprotective Effects and Therapeutic Potential of Dichloroacetate: Targeting Metabolic Disorders in Nervous System Diseases

  2023cites this paper
• Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses.

  2023cites this paper
• A Family of Cagelike Mn-Silsesquioxane/Bathophenanthroline Complexes: Synthesis, Structure, and Catalytic and Antifungal Activity.

  2023cites this paper
• Structural and morphological changes of breast cancer cells induced by iron(II) complexes.

  2022cites this paper
• Chemistry towards Biology—Instruct: Snapshot

  2022cites this paper
• Evaluation of the in vitro cytogenotoxic profile of the silver(I) metal complex with furosemide (Ag-FSE)

  2022cites this paper
• Stability of a half-sandwich Os(II) complex with indomethacin-functionalized ligand in the presence of carboxypeptidase A.

  2022cites this paper
• Metal complexes against breast cancer stem cells.

  2021cites this paper
• Cis,cis,trans-[PtIVCl2(NH3)2(perillato)2], a dual-action prodrug with excellent cytotoxic and antimetastatic activity.

  2021cites this paper
• Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer.

  2021cites this paper
• Unexpected solution behaviour of ester-functionalized half-sandwich Ru(II) and Ir(III) complexes.

  2021cites this paper
• Elemental mapping of half-sandwich azopyridine osmium arene complexes in cancer cells

  2021cites this paper
• Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance.

  2021cites this paper
• Evaluation of the In Vitro and In Vivo Efficacy of Ruthenium Polypyridyl Compounds against Breast Cancer

  2021cites this paper
• Synthesis, structure and cytotoxicity of N,N and N,O coordinated RuII complexes of 3-aminobenzoate Schiff bases against triple-negative breast cancer.

  2021cites this paper
• Covalent and noncovalent interactions of coordination compounds with DNA: An overview.

  2021cites this paper
• Multinuclear biologically active Ru, Rh, Os and Ir arene complexes

  2020cites this paper
• A cytotoxic nitrido-osmium(VI) complex induces caspase-mediated apoptosis in HepG2 cancer cells.

  2020cites this paper
• p-Cymene metallo-derivatives: An overview on anticancer activity.

  2020cites this paper
• Cytotoxic dimeric half‐sandwich Ru(II), Os(II) and Ir(III) complexes containing the 4,4′‐biphenyl‐based bridging ligands

  2020cites this paper
• AqF026 may act as a cancer therapeutic agent via inducing cancer cell oncosis.

  2020cites this paper
• Rationally Designed Ruthenium Complexes for Breast Cancer Therapy

  2020cites this paper
• Azaindoles: Suitable ligands of cytotoxic transition metal complexes.

  2019cites this paper
• Non-platinum complexes containing releasable biologically active ligands

  2019cites this paper
• Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications

  2019cites this paper
• Ruthenium(II)–Arene Thiocarboxylates: Identification of a Stable Dimer Selectively Cytotoxic to Invasive Breast Cancer Cells

  2019cites this paper
• Luminescent ruthenium(II) polypyridyl complexes acted as radiosensitizer for pancreatic cancer by enhancing radiation-induced DNA damage

  2019cites this paper
• An anticancer Os(II) bathophenanthroline complex as a human breast cancer stem cell-selective, mammosphere potent agent that kills cells by necroptosis

  2019cites this paper
• Discovery of selective, antimetastatic and anti-cancer stem cell metallohelices via post-assembly modification

  2019cites this paper